Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2013 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ATRICURE INC | 40 | Q3 2023 | 9.7% |
NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
PFIZER INC | 39 | Q2 2023 | 0.9% |
BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
OMNICELL INC | 33 | Q3 2023 | 7.7% |
QUIDEL CORP | 33 | Q4 2021 | 3.7% |
NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D/A | 2024-04-09 |
4 | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.